2015
The CVB recently updated VS Memorandum 800.213: Licensing Guidelines for Production Platform-Based, Non-Replicating, Nonviable Products. This Memo could impact licensing plans for products that are currently being manufactured under 9 CFR 107.1, and also addresses platform-based prescription products.
No comments so far!